环孢素A个体化用药临床预后的实验室检查指标研究进展

胡锦炜; 朱怀军; 劳茜莹; 李丹滢

doi:10.6039/j.issn.1001-0408.2022.18.22

您当前的位置：

首页 >

文章列表页 >

环孢素A个体化用药临床预后的实验室检查指标研究进展

“一切为了人民健康——我们这十年”专栏 | 更新时间：2023-02-22

- 环孢素A个体化用药临床预后的实验室检查指标研究进展
- Research progress on laboratory examination index of clinical prognosis in individualization of cyclosporine A
- 中国药房 2022年33卷第18期页码：2285-2289
- 作者机构：
  
  1.南京大学医学院附属鼓楼医院药学部，南京　210008
  2.南京中医药大学中西医结合鼓楼临床医学院，南京　210008
- 作者简介：
  
  硕士研究生。研究方向：临床药学。E-mail：hjviv126＠163.com
  副主任药师，硕士。研究方向：医院药学。E-mail：haidi_li＠126.com
- 基金信息：
  
  Δ 基金项目国家自然科学基金青年科学基金资助项目(81803634)
- DOI：10.6039/j.issn.1001-0408.2022.18.22
  中图分类号： R969
- 纸质出版日期：2022-09-30，
  
  收稿日期：2022-02-25，
  
  修回日期：2022-08-17，
扫描看全文
胡锦炜,朱怀军,劳茜莹等.环孢素A个体化用药临床预后的实验室检查指标研究进展 ^Δ[J].中国药房,2022,33(18):2285-2289.

HU Jinwei,ZHU Huaijun,LAO Qianying,et al.Research progress on laboratory examination index of clinical prognosis in individualization of cyclosporine A[J].ZHONGGUO YAOFANG,2022,33(18):2285-2289.
胡锦炜,朱怀军,劳茜莹等.环孢素A个体化用药临床预后的实验室检查指标研究进展 ^Δ[J].中国药房,2022,33(18):2285-2289. DOI： 10.6039/j.issn.1001-0408.2022.18.22.

HU Jinwei,ZHU Huaijun,LAO Qianying,et al.Research progress on laboratory examination index of clinical prognosis in individualization of cyclosporine A[J].ZHONGGUO YAOFANG,2022,33(18):2285-2289. DOI： 10.6039/j.issn.1001-0408.2022.18.22.

摘要

环孢素A在器官移植以及自身免疫疾病治疗中应用广泛，由于该药存在明显的个体间代谢差异，临床使用时需要根据患者血药浓度调整给药剂量。但环孢素A的血药浓度并不能准确反映其临床预后。本文围绕外周血单个核细胞内环孢素A浓度、钙调磷酸酶活性和T细胞功能以及环孢素A代谢物浓度4个实验室检查指标，综述其与环孢素A药动学以及临床预后的相关性。结果发现以上指标对患者使用环孢素A的临床预后情况有一定的预示作用，可弥补血药浓度监测的不足，但其临床实用性还需进一步提高。

Abstract

Cyclosporine A is widely used in organ transplantation and autoimmune diseases. Due to the obvious differences in metabolism between individuals， the dosage should be adjusted according to the patient’s blood concentration during clinical use. But the blood concentration does not reflect accurately its clinical prognosis. This article focuses on the four laboratory examination indexes following aspects： the cyclosporine A concentration of peripheral blood mononuclear cells， calcineurin activity， T cell function and metabolite concentration of cyclosporine A. The relationship between them and the pharmacokinetics of cyclosporine and clinical prognosis were reviewed. It’s found that the above indicators have a certain predictive effect on the clinical prognosis of patients receiving cyclosporine A， which can make up for the insufficiency of blood drug concentration monitoring， and the clinical practicability needs to be further improved.

关键词

环孢素A治疗药物监测临床疗效安全性实验室检查指标

Keywords

therapeutic drug monitoringclinical efficacysafetylaboratory examination index

references

YANG X Q，FENG P，YIN Y，et al. Cyclosporine biosynthesis in Tolypocladium inflatum benefits fungal adaptation to the environment[J]. mBio，2018，9（5）：e01211-e01218.

BOREL J F. Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity[J]. Immuno-logy，1976，31（4）：631-641.

SURVASE S A，KAGLIWAL L D，ANNAPURE U S，et al. Cyclosporin A：a review on fermentative production，downstream processing and pharmacological applications[J]. Biotechnol Adv，2011，29（4）：418-435.

U.S. Food and Drug Administration. Novartis label：neoral soft gelatin capsules（cyclosporine capsules，USP）：2015[EB/OL]. [2021-12-29]. https：//www.accessdata.fda.gov/drugsatfda_docs/label/2019/050715s035https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050715s035，050716s038lbl.pdf.

OGAWA H，KAMEDA H，AMANO K，et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice[J]. Lupus，2010，19（2）：162-169.

FANOURIAKIS A，KOSTOPOULOU M，ALUNNO A，et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis，2019，78（6）：736-745.

张文，厉小梅，徐东，等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志，2020，59（4）：269-276.

CHOI P Y，RONCOLATO F，BADOUX X，et al. A novel triple therapy for ITP using high-dose dexamethasone，low-dose rituximab，and cyclosporine（TT4）[J]. Blood，2015，126（4）：500-503.

PATOCKA J，NEPOVIMOVA E，KUCA K，et al. Cyclosporine A：chemistry and toxicity：a review[J]. Curr Med Chem，2021，28（20）：3925-3934.

LI W L，LI R，LIU H J，et al. A comparison of liquid chromatography-tandem mass spectrometry（LC-MS/MS）and enzyme-multiplied immunoassay technique（EMIT）for the determination of the cyclosporin A concentration in whole blood from Chinese patients[J]. Biosci Trends，2017，11（4）：475-482.

TAFAZOLI A，DADASHZADEH S，MEHDIZADEH M，et al. Evaluation of cyclosporine pharmacokinetic，monitoring，and dosing parameters for GVHD prophylaxis in hematopoietic stem cell transplant（HSCT）recipients[J]. Iran J Pharm Res，2019，18（Suppl 1）：302-314.

LIDDICOAT A M，LAVELLE E C. Modulation of innate immunity by cyclosporine A[J]. Biochem Pharmacol，2019，163：472-480.

CAPRON A，HAUFROID V，WALLEMACQ P. Intra-cellular immunosuppressive drugs monitoring：a step forward towards better therapeutic efficacy after organ transplantation? [J]. Pharmacol Res，2016，111：610-618.

LEMAITRE F，VETHE N T，D’AVOLIO A，et al. Measu-ring intracellular concentrations of calcineurin inhibitors：expert consensus from the international association of therapeutic drug monitoring and clinical toxicology expert panel[J]. Ther Drug Monit，2020，42（5）：665-670.

FALCK P，ASBERG A，GULDSETH H，et al. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients[J]. Transplantation，2008，85（2）：179-184.

CRETTOL S，VENETZ J P，FONTANA M，et al. Inf-luence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients[J]. Pharmacogenet Genomics，2008，18（4）：307-315.

VANHOVE T，ANNAERT P，KUYPERS D R. Clinical determinants of calcineurin inhibitor disposition：a mechanistic review[J]. Drug Metab Rev，2016，48（1）：88-112.

BARBARI A G，MASRI M A，STEPHAN A G，et al. Cyclosporine lymphocyte maximum level：a new alternative for cyclosporine monitoring in kidney transplantation[J]. Exp Clin Transplant，2005，3（1）：293-300.

SANQUER S，SCHWARZINGER M，MAURY S，et al. Calcineurin activity as a functional index of immunosuppression after allogeneic stem-cell transplantation[J]. Transplantation，2004，77（6）：854-858.

CARUSO R，PERICO N，CATTANEO D，et al. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients[J]. Clin Chem，2001，47（9）：1679-1687.

FUKUDO M，YANO I，MASUDA S，et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients[J]. Clin Pharmacol Ther，2005，78（2）：168-181.

PAI S Y，FRUMAN D A，LEONG T，et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A[J]. Blood，1994，84（11）：3974-3979.

GUADA M，BELOQUI A，KUMAR M N V R，et al. Reformulating Cyclosporine A（CsA）：more than just a life cycle management strategy[J]. J Control Release，2016，225：269-282.

BARTEN M J，TARNOK A，GARBADE J，et al. Pharmacodynamics of T-cell function for monitoring immunosuppression[J]. Cell Prolif，2007，40（1）：50-63.

SERHAT INALOZ H，OZTURK S，AKCALI C，et al. Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria：a clinical and immunological evaluation[J]. J Dermatol，2008，35（5）：276-282.

ZAHN A，SCHOTT N，HINZ U，et al. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression：the first clinical trial in liver allograft recipients[J]. Liver Transpl，2011，17（4）：466-473.

MILLÁN O，RUIZ P，FORTUNA V，et al. Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients[J]. Liver Int，2020，40（4）：931-946.

SOMMERER C，BROCKE J，BRUCKNER T，et al. Improved pulse wave velocity and renal function in individua-lized calcineurin inhibitor treatment by immunomonito-ring：the randomized controlled calcineurin inhibitor-sparing trial[J]. Transplantation，2018，102（3）：510-520.

SOMMERER C，GIESE T. Nuclear factor of activated T cells-regulated gene expression as predictive biomarker of personal response to calcineurin inhibitors[J]. Ther Drug Monit，2016，38（Suppl 1）：S50-S56.

CHRISTIANS U，SEWING K F. Cyclosporin metabolism in transplant patients[J]. Pharmacol Ther，1993，57（2/3）：291-345.

WU Q H，KUCA K. Metabolic pathway of cyclosporine A and its correlation with nephrotoxicity[J]. Curr Drug Metab，2019，20（2）：84-90.

HRYNIEWIECKA E，ŻEGARSKA J，ŻOCHOWSKA D，et al. Cyclosporine metabolites’ metabolic ratios may be markers of cardiovascular disease in kidney transplant recipients treated with cyclosporine A-based immunosuppression regimens[J]. Cardiovasc Toxicol，2019，19（3）：255-263.

ZEGARSKA J，HRYNIEWIECKA E，ZOCHOWSKA D，et al. Higher concentrations of cyclosporine metabolites in liver transplant recipients with a history of viral and bac-terial infections[J]. Transplant Proc，2020，52（8）：2503-2506.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

9例利妥昔单抗序贯贝利尤单抗治疗重症系统性红斑狼疮的临床观察

4种蛇毒血凝酶联合质子泵抑制剂用于非静脉曲张上消化道出血疗效和安全性的网状Meta分析

紫杉醇新辅助化疗单周方案对比密集方案用于乳腺癌的疗效和安全性评价